Research programme: cyclin-dependent kinase inhibitors - Cyclacel

Drug Profile

Research programme: cyclin-dependent kinase inhibitors - Cyclacel

Alternative Names: 2-Anilino-4-(thiazol-5-yl)-pyrimidine - Cyclacel; CCT-68127; CYC 11056; CYC400 series - Cyclacel; Second-generation CDK inhibitors - Cyclacel; Tri-substituted purines - Cyclacel

Latest Information Update: 28 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cyclacel Pharmaceuticals
  • Class Purines; Pyrimidines; Small molecules
  • Mechanism of Action Cyclin dependent kinase 9 inhibitors; Cyclin-dependent kinase 2 inhibitors; Cyclin-dependent kinase 5 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Acute myeloid leukaemia; Cancer; Neuroblastoma; Precursor cell lymphoblastic leukaemia-lymphoma
  • No development reported Glomerulonephritis

Most Recent Events

  • 28 Apr 2018 No recent reports of development identified for preclinical development in Glomerulonephritis in United Kingdom (PO)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in United Kingdom (PO)
  • 16 Apr 2016 Pharmacodynamics data from a preclinical study in Cancer presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top